$SEEL
Seelos Therapeutics Inc Stock $seel

$seel Overview Financials Valuation SEC Filings Company Website

2015 Q4 Form 10-Q Financial Statement

#000101749115000083 Filed on November 05, 2015

Income Statement

Concept	2015 Q4	2015 Q3	2014 Q3
Revenue	$2.629M	$1.273M	$1.898M
YoY Change	37.86%	-32.93%	6678.57%
Cost Of Revenue	$40.00K	$142.0K	$0.00
YoY Change	-88.89%		-100.0%
Gross Profit	$2.591M	$1.131M	$1.413M
YoY Change	67.27%	-19.96%	10769.23%
Gross Profit Margin	98.55%	88.85%	74.45%
Selling, General & Admin	$2.340M	$2.410M	$2.720M
YoY Change	-15.22%	-11.4%	-5.23%
% of Gross Profit	90.31%	213.09%	192.5%
Research & Development	$3.660M	$4.611M	$1.876M
YoY Change	-76.94%	145.79%	104.13%
% of Gross Profit	141.26%	407.69%	132.77%
Depreciation & Amortization	$80.00K	$70.00K	$60.00K
YoY Change	14.29%	16.67%	200.0%
% of Gross Profit	3.09%	6.19%	4.25%
Operating Expenses	$6.000M	$7.023M	$4.595M
YoY Change	-67.79%	52.84%	44.68%
Operating Profit	-$3.409M	-$5.892M	-$3.182M
YoY Change	-80.04%	85.17%	0.6%
Interest Expense	$2.950M	-$267.0K	-$44.00K
YoY Change	-2558.33%	506.82%	-74.71%
% of Operating Profit
Other Income/Expense, Net	-$1.770M	$858.0K	$50.00K
YoY Change	17600.0%	1616.0%	-238.89%
Pretax Income	-$2.330M	-$5.030M	-$3.130M
YoY Change	-86.52%	60.7%	-2.19%
Income Tax	$0.00	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$2.332M	-$5.034M	-$3.113M
YoY Change	-86.51%	61.71%	4.29%
Net Earnings / Revenue	-88.7%	-395.44%	-164.01%
Basic Earnings Per Share			-$0.08
Diluted Earnings Per Share	-$13.71M	-$29.59M	-$0.08
COMMON SHARES
Basic Shares Outstanding	50.41M shares	50.41M shares	38.10M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2015 Q4	2015 Q3	2014 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$3.890M	$5.810M	$16.11M
YoY Change	-65.88%	-63.94%	-21.87%
Cash & Equivalents	$3.887M	$5.809M	$16.11M
Short-Term Investments
Other Short-Term Assets	$1.340M	$1.640M	$1.110M
YoY Change	42.55%	47.75%	65.67%
Inventory	$469.0K	$142.0K	$321.0K
Prepaid Expenses
Receivables	$519.0K	$575.0K	$829.0K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$6.217M	$8.165M	$18.37M
YoY Change	-53.22%	-55.55%	-15.19%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.290M	$1.294M	$1.319M
YoY Change	-5.01%	-1.9%	140.26%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$274.0K	$141.0K	$106.0K
YoY Change	69.14%	33.02%	17.78%
Total Long-Term Assets	$1.564M	$1.435M	$1.425M
YoY Change	2.89%	0.7%	123.0%
TOTAL ASSETS
Total Short-Term Assets	$6.217M	$8.165M	$18.37M
Total Long-Term Assets	$1.564M	$1.435M	$1.425M
Total Assets	$7.781M	$9.600M	$19.80M
YoY Change	-47.46%	-51.51%	-11.23%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.580M	$420.0K	$1.220M
YoY Change	83.72%	-65.57%	96.77%
Accrued Expenses	$3.343M	$2.869M	$1.825M
YoY Change	-26.61%	57.21%	-16.28%
Deferred Revenue
YoY Change
Short-Term Debt	$9.400M	$2.680M	$1.200M
YoY Change	6166.67%	123.33%	-16.67%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$15.68M	$6.855M	$6.386M
YoY Change	127.11%	7.34%	-23.98%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$7.190M	$0.00
YoY Change	-100.0%		-100.0%
Other Long-Term Liabilities	$200.0K	$190.0K	$58.00K
YoY Change	-44.13%	227.59%	-54.33%
Total Long-Term Liabilities	$200.0K	$190.0K	$58.00K
YoY Change	-44.13%	227.59%	-54.33%
TOTAL LIABILITIES
Total Short-Term Liabilities	$15.68M	$6.855M	$6.386M
Total Long-Term Liabilities	$200.0K	$190.0K	$58.00K
Total Liabilities	$17.73M	$17.51M	$7.800M
YoY Change	37.51%	124.5%	-24.67%
SHAREHOLDERS EQUITY
Retained Earnings	-$308.9M	-$306.5M	-$272.6M
YoY Change	6.56%	12.47%	2.19%
Common Stock	$298.9M	$298.6M	$284.6M
YoY Change	2.45%	4.95%	2.11%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$9.944M	-$7.911M	$12.00M
YoY Change
Total Liabilities & Shareholders Equity	$7.781M	$9.600M	$19.80M
YoY Change	-47.46%	-51.51%	-11.23%

Cashflow Statement

Concept	2015 Q4	2015 Q3	2014 Q3
OPERATING ACTIVITIES
Net Income	-$2.332M	-$5.034M	-$3.113M
YoY Change	-86.51%	61.71%	4.29%
Depreciation, Depletion And Amortization	$80.00K	$70.00K	$60.00K
YoY Change	14.29%	16.67%	200.0%
Cash From Operating Activities	-$1.310M	-$6.590M	-$4.080M
YoY Change	-85.64%	61.52%	-5.77%
INVESTING ACTIVITIES
Capital Expenditures	-$120.0K	-$30.00K	-$70.00K
YoY Change	50.0%	-57.14%
Acquisitions
YoY Change
Other Investing Activities	$0.00	$10.00K	$0.00
YoY Change			-100.0%
Cash From Investing Activities	-$120.0K	-$20.00K	-$60.00K
YoY Change	50.0%	-66.67%	-137.5%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-490.0K	4.990M	2.840M
YoY Change	-110.91%	75.7%	9366.67%
NET CHANGE
Cash From Operating Activities	-1.310M	-6.590M	-4.080M
Cash From Investing Activities	-120.0K	-20.00K	-60.00K
Cash From Financing Activities	-490.0K	4.990M	2.840M
Net Change In Cash	-1.920M	-1.620M	-1.300M
YoY Change	-59.24%	24.62%	-68.6%
FREE CASH FLOW
Cash From Operating Activities	-$1.310M	-$6.590M	-$4.080M
Capital Expenditures	-$120.0K	-$30.00K	-$70.00K
Free Cash Flow	-$1.190M	-$6.560M	-$4.010M
YoY Change	-86.84%	63.59%	-7.39%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2014Q4	apri	Accrued License Fees AccruedLicenseFees	2500000	USD
CY2015Q3	apri	Accrued License Fees AccruedLicenseFees	0	USD
	apri	Increase Decrease In Short Term Liability Arising From Deconsolidation Of Subsidiaries IncreaseDecreaseInShortTermLiabilityArisingFromDeconsolidationOfSubsidiaries	-2000000	USD
	apri	Increase Decrease In Short Term Liability Arising From Deconsolidation Of Subsidiaries IncreaseDecreaseInShortTermLiabilityArisingFromDeconsolidationOfSubsidiaries	0	USD
CY2014Q4	apri	Research And Development Accrued Expense ResearchAndDevelopmentAccruedExpense	838000	USD
CY2015Q3	apri	Research And Development Accrued Expense ResearchAndDevelopmentAccruedExpense	1724000	USD
	apri	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Exercisable Weighted Average Remaining Contractual Term ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageRemainingContractualTerm	P3Y4M7D
CY2014	apri	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Outstanding Weighted Average Remaining Contractual Term One ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTermOne	P2Y8M7D
	apri	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Outstanding Weighted Average Remaining Contractual Term One ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTermOne	P3Y4M7D
	apri	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Forfeiture Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate	0.0360
	apri	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Forfeiture Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate	0.1154
CY2015Q3	apri	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber	10034099	shares
CY2015Q3	apri	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageExercisePrice	3.19
	apri	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisesInPeriodWeightedAverageExercisePrice	0.00
	apri	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice	1.81
CY2014Q4	apri	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice	3.83
CY2015Q3	apri	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice	3.19
	apri	Share Based Compensation Arrangement By Share Based Payment Award Non Options Equity Instruments Forfeited Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsForfeitedWeightedAverageExercisePrice	0.00
	apri	Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Issued Weighted Average Remaining Contractual Terms SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedWeightedAverageRemainingContractualTerms	P6Y6M7D
CY2014Q1	apri	Stock Returned From Contract Settlement Shares StockReturnedFromContractSettlementShares	388888	shares
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2015
	dei	Document Period End Date DocumentPeriodEndDate	2015-09-30
	dei	Document Type DocumentType	10-Q
	dei	Entity Central Index Key EntityCentralIndexKey	0001017491
CY2015Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	50414481	shares
	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
	dei	Entity Registrant Name EntityRegistrantName	APRICUS BIOSCIENCES, INC.
	dei	Trading Symbol TradingSymbol	APRI
CY2014Q4	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	860000	USD
CY2015Q3	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	417000	USD
CY2014Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	678000	USD
CY2015Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	575000	USD
	us-gaap	Accretion Expense Including Asset Retirement Obligations AccretionExpenseIncludingAssetRetirementObligations	128000	USD
	us-gaap	Accretion Expense Including Asset Retirement Obligations AccretionExpenseIncludingAssetRetirementObligations	174000	USD
CY2014Q4	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	1112000	USD
CY2015Q3	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	879000	USD
CY2014Q4	us-gaap	Accrued Environmental Loss Contingencies Current AccruedEnvironmentalLossContingenciesCurrent	126000	USD
CY2015Q3	us-gaap	Accrued Environmental Loss Contingencies Current AccruedEnvironmentalLossContingenciesCurrent	75000	USD
CY2014Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	4555000	USD
CY2015Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2869000	USD
CY2014Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	625000	USD
CY2015Q3	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	610000	USD
CY2014Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	291727000	USD
CY2015Q3	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	298582000	USD
	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	0	USD
	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	75000	USD
CY2014Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	419000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1456000	USD
CY2015Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	299000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	912000	USD
CY2014Q4	us-gaap	Assets Assets	14809000	USD
CY2015Q3	us-gaap	Assets Assets	9600000	USD
CY2014Q4	us-gaap	Assets Current AssetsCurrent	13289000	USD
CY2015Q3	us-gaap	Assets Current AssetsCurrent	8165000	USD
CY2014Q4	us-gaap	Capital Lease Obligations Noncurrent CapitalLeaseObligationsNoncurrent	5000	USD
CY2015Q3	us-gaap	Capital Lease Obligations Noncurrent CapitalLeaseObligationsNoncurrent	1000	USD
CY2013Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	21405000	USD
CY2014Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	16109000	USD
CY2014Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	11400000	USD
CY2015Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	5809000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-5296000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-5591000	USD
	us-gaap	Cash Provided By Used In Investing Activities Discontinued Operations CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations	675000	USD
	us-gaap	Cash Provided By Used In Investing Activities Discontinued Operations CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations	0	USD
	us-gaap	Cash Provided By Used In Operating Activities Discontinued Operations CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations	16000	USD
	us-gaap	Cash Provided By Used In Operating Activities Discontinued Operations CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations	0	USD
CY2015Q3	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	10034099	shares
CY2014Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2015Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2014Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2015Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2014Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2015Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2014Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	44330006	shares
CY2015Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	50414481	shares
CY2014Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	44330006	shares
CY2015Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	50414481	shares
CY2014Q4	us-gaap	Common Stock Value CommonStockValue	44000	USD
CY2015Q3	us-gaap	Common Stock Value CommonStockValue	50000	USD
CY2014Q3	us-gaap	Cost Of Goods Sold CostOfGoodsSold	485000	USD
	us-gaap	Cost Of Goods Sold CostOfGoodsSold	560000	USD
CY2015Q3	us-gaap	Cost Of Goods Sold CostOfGoodsSold	142000	USD
	us-gaap	Cost Of Goods Sold CostOfGoodsSold	884000	USD
CY2014Q3	us-gaap	Deconsolidation Gain Or Loss Amount DeconsolidationGainOrLossAmount	0	USD
	us-gaap	Deconsolidation Gain Or Loss Amount DeconsolidationGainOrLossAmount	846000	USD
CY2015Q3	us-gaap	Deconsolidation Gain Or Loss Amount DeconsolidationGainOrLossAmount	0	USD
	us-gaap	Deconsolidation Gain Or Loss Amount DeconsolidationGainOrLossAmount	0	USD
CY2014Q4	us-gaap	Deferred Compensation Liability Classified Noncurrent DeferredCompensationLiabilityClassifiedNoncurrent	312000	USD
CY2015Q3	us-gaap	Deferred Compensation Liability Classified Noncurrent DeferredCompensationLiabilityClassifiedNoncurrent	179000	USD
CY2014Q4	us-gaap	Deferred Compensation Liability Current DeferredCompensationLiabilityCurrent	176000	USD
CY2015Q3	us-gaap	Deferred Compensation Liability Current DeferredCompensationLiabilityCurrent	177000	USD
CY2014Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	41000	USD
CY2015Q3	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	10000	USD
CY2014Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	226000	USD
CY2015Q3	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	7000	USD
CY2014Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	1000000	USD
CY2015Q3	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	0	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	102000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	224000	USD
CY2014Q4	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	0	USD
CY2015Q3	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	3273000	USD
CY2015Q1	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	5100000	USD
CY2014Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.08
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.12
CY2015Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.10
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.34
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	0	USD
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-1804000	USD
CY2014Q3	us-gaap	Gain Loss On Contract Termination GainLossOnContractTermination	0	USD
	us-gaap	Gain Loss On Contract Termination GainLossOnContractTermination	910000	USD
	us-gaap	Gain Loss On Contract Termination GainLossOnContractTermination	900000	USD
CY2015Q3	us-gaap	Gain Loss On Contract Termination GainLossOnContractTermination	0	USD
	us-gaap	Gain Loss On Contract Termination GainLossOnContractTermination	0	USD
	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	0	USD
	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	-56000	USD
CY2014Q3	us-gaap	Gain Loss On Sale Of Stock In Subsidiary Or Equity Method Investee GainLossOnSaleOfStockInSubsidiaryOrEquityMethodInvestee	0	USD
	us-gaap	Gain Loss On Sale Of Stock In Subsidiary Or Equity Method Investee GainLossOnSaleOfStockInSubsidiaryOrEquityMethodInvestee	50000	USD
CY2015Q3	us-gaap	Gain Loss On Sale Of Stock In Subsidiary Or Equity Method Investee GainLossOnSaleOfStockInSubsidiaryOrEquityMethodInvestee	0	USD
	us-gaap	Gain Loss On Sale Of Stock In Subsidiary Or Equity Method Investee GainLossOnSaleOfStockInSubsidiaryOrEquityMethodInvestee	0	USD
	us-gaap	Gain Or Loss On Sale Of Stock In Subsidiary GainOrLossOnSaleOfStockInSubsidiary	50000	USD
	us-gaap	Gain Or Loss On Sale Of Stock In Subsidiary GainOrLossOnSaleOfStockInSubsidiary	0	USD
CY2014Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2719000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	8655000	USD
CY2015Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2412000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	8177000	USD
CY2014Q3	us-gaap	Gross Profit GrossProfit	1413000	USD
	us-gaap	Gross Profit GrossProfit	6792000	USD
CY2015Q3	us-gaap	Gross Profit GrossProfit	1131000	USD
	us-gaap	Gross Profit GrossProfit	1326000	USD
CY2014Q3	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-3132000	USD
	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-5189000	USD
CY2015Q3	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-5034000	USD
	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-16691000	USD
CY2014Q3	us-gaap	Income Loss From Continuing Operations Per Basic And Diluted Share IncomeLossFromContinuingOperationsPerBasicAndDilutedShare	-0.08
	us-gaap	Income Loss From Continuing Operations Per Basic And Diluted Share IncomeLossFromContinuingOperationsPerBasicAndDilutedShare	-0.14
CY2015Q3	us-gaap	Income Loss From Continuing Operations Per Basic And Diluted Share IncomeLossFromContinuingOperationsPerBasicAndDilutedShare	-0.10
	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-163000	USD
	us-gaap	Income Loss From Continuing Operations Per Basic And Diluted Share IncomeLossFromContinuingOperationsPerBasicAndDilutedShare	-0.34
CY2014Q3	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	19000	USD
	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	691000	USD
CY2015Q3	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	0	USD
	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	0	USD
CY2014Q3	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic And Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare	0.00
	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic And Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare	0.02
CY2015Q3	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic And Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare	0.00
	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic And Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare	0.00
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	295000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-443000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	770000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-103000	USD
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-239000	USD
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-1686000	USD
	us-gaap	Increase Decrease In Accrued Salaries IncreaseDecreaseInAccruedSalaries	-99000	USD
	us-gaap	Increase Decrease In Accrued Salaries IncreaseDecreaseInAccruedSalaries	-233000	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	484000	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-1219000	USD
	us-gaap	Increase Decrease In Derivative Liabilities IncreaseDecreaseInDerivativeLiabilities	-517000	USD
	us-gaap	Increase Decrease In Derivative Liabilities IncreaseDecreaseInDerivativeLiabilities	0	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-15000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-133000	USD
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	15000	USD
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	12000	USD
	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-160000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	598000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	718000	USD
	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	50000	USD
	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	-10000	USD
CY2015Q3	us-gaap	Interest Expense Debt InterestExpenseDebt	300000	USD
	us-gaap	Interest Expense Debt InterestExpenseDebt	600000	USD
CY2014Q3	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-44000	USD
	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-220000	USD
CY2015Q3	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-254000	USD
	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-557000	USD
CY2014Q4	us-gaap	Inventory Net InventoryNet	275000	USD
CY2015Q3	us-gaap	Inventory Net InventoryNet	142000	USD
CY2014Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	106000	USD
CY2015Q3	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	78000	USD
CY2014Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	169000	USD
CY2015Q3	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	64000	USD
CY2014Q4	us-gaap	Liabilities Liabilities	12890000	USD
CY2015Q3	us-gaap	Liabilities Liabilities	17511000	USD
CY2014Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	14809000	USD
CY2015Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	9600000	USD
CY2014Q4	us-gaap	Liabilities Current LiabilitiesCurrent	6906000	USD
CY2015Q3	us-gaap	Liabilities Current LiabilitiesCurrent	6855000	USD
CY2014Q3	us-gaap	Licenses Revenue LicensesRevenue	1500000	USD
	us-gaap	Licenses Revenue LicensesRevenue	6954000	USD
CY2015Q3	us-gaap	Licenses Revenue LicensesRevenue	1000000	USD
	us-gaap	Licenses Revenue LicensesRevenue	1350000	USD
CY2014Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	4626000	USD
CY2015Q3	us-gaap	Long Term Notes Payable LongTermNotesPayable	7193000	USD
	us-gaap	Net Cash Provided By Used In Discontinued Operations NetCashProvidedByUsedInDiscontinuedOperations	691000	USD
	us-gaap	Net Cash Provided By Used In Discontinued Operations NetCashProvidedByUsedInDiscontinuedOperations	0	USD
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	3376000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	15957000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-450000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-216000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-8913000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-21332000	USD
CY2014Q3	us-gaap	Net Income Loss NetIncomeLoss	-3113000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-4498000	USD
CY2015Q3	us-gaap	Net Income Loss NetIncomeLoss	-5034000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-16691000	USD
CY2014Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	50000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	291000	USD
CY2015Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	858000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	1146000	USD
CY2014Q4	us-gaap	Notes Payable Current NotesPayableCurrent	153000	USD
CY2015Q3	us-gaap	Notes Payable Current NotesPayableCurrent	2683000	USD
	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	Segment
CY2014Q3	us-gaap	Operating Expenses OperatingExpenses	4595000	USD
	us-gaap	Operating Expenses OperatingExpenses	12272000	USD
CY2015Q3	us-gaap	Operating Expenses OperatingExpenses	7023000	USD
	us-gaap	Operating Expenses OperatingExpenses	19163000	USD
CY2014Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-3182000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-5480000	USD
CY2015Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-5892000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-17837000	USD
CY2014Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	290000	USD
CY2015Q3	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	283000	USD
CY2014Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	162000	USD
CY2015Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	141000	USD
CY2014Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	358000	USD
CY2015Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	190000	USD
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	0	USD
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-35000	USD
CY2014Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	94000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	511000	USD
CY2015Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	1112000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	1703000	USD
	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	42000	USD
	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	0	USD
CY2015Q1	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	100000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	500000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	216000	USD
CY2015Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1294000	USD
	us-gaap	Repayments Of Long Term Capital Lease Obligations RepaymentsOfLongTermCapitalLeaseObligations	25000	USD
CY2014Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
	us-gaap	Repayments Of Long Term Capital Lease Obligations RepaymentsOfLongTermCapitalLeaseObligations	5000	USD
CY2014Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1876000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	5423000	USD
CY2015Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2014Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2015Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2014Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2015Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2014Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2015Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2015Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4611000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	10986000	USD
CY2014Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	290000	USD
CY2015Q3	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	280000	USD
CY2014Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-289852000	USD
CY2015Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-306543000	USD
CY2014Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2015Q3	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2014Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	646000	USD
CY2015Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1359000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	5018000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	10869000	USD
CY2015Q1	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	10900000	USD
	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	0	USD
	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	5000000	USD
	us-gaap	Proceeds From Repayments Of Short Term Debt ProceedsFromRepaymentsOfShortTermDebt	-1525000	USD
	us-gaap	Proceeds From Repayments Of Short Term Debt ProceedsFromRepaymentsOfShortTermDebt	0	USD
	us-gaap	Proceeds From Sales Of Business Affiliate And Productive Assets ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets	50000	USD
	us-gaap	Proceeds From Sales Of Business Affiliate And Productive Assets ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets	0	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	0	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	83000	USD
CY2014Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1358000	USD
CY2014Q3	us-gaap	Royalty Revenue RoyaltyRevenue	0	USD
	us-gaap	Royalty Revenue RoyaltyRevenue	0	USD
CY2015Q3	us-gaap	Royalty Revenue RoyaltyRevenue	188000	USD
	us-gaap	Royalty Revenue RoyaltyRevenue	351000	USD
CY2014Q3	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	398000	USD
	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	398000	USD
CY2015Q3	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	85000	USD
	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	509000	USD
CY2014Q3	us-gaap	Sales Revenue Net SalesRevenueNet	1898000	USD
	us-gaap	Sales Revenue Net SalesRevenueNet	7352000	USD
CY2015Q3	us-gaap	Sales Revenue Net SalesRevenueNet	1273000	USD
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0137
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised	0	shares
	us-gaap	Sales Revenue Net SalesRevenueNet	2210000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	1456000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	912000	USD
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.021
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0187
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0158
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Forfeitures ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures	0	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted	3174417	shares
CY2014Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	6859682	shares
CY2015Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	10034099	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	953000	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	1393000	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	1.61
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	1.07
CY2014Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3956000	shares
CY2015Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	4355000	shares
CY2014Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	2.58
CY2015Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	2010
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	2050
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	3540
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	1440
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	41000	shares
CY2014Q4	us-gaap	Stockholders Equity StockholdersEquity	1919000	USD
CY2015Q3	us-gaap	Stockholders Equity StockholdersEquity	-7911000	USD
CY2014Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	39059000	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	38282000	shares
CY2015Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	50414000	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	49497000	shares

Files In Submission

Name	View Source	Status
0001017491-15-000083-index-headers.html	Edgar Link	pending
0001017491-15-000083-index.html	Edgar Link	pending
0001017491-15-000083.txt	Edgar Link	pending
0001017491-15-000083-xbrl.zip	Edgar Link	pending
allerganimages.jpg	Edgar Link	pending
apri-20150930.xml	Edgar Link	completed
apri-20150930.xsd	Edgar Link	pending
apri-20150930_cal.xml	Edgar Link	unprocessable
apri-20150930_def.xml	Edgar Link	unprocessable
apri-20150930_lab.xml	Edgar Link	unprocessable
apri-20150930_pre.xml	Edgar Link	unprocessable
apri9301510q.htm	Edgar Link	pending
apri93015ex101.htm	Edgar Link	pending
apri93015ex311.htm	Edgar Link	pending
apri93015ex312.htm	Edgar Link	pending
apri93015ex321.htm	Edgar Link	pending
apri93015ex322.htm	Edgar Link	pending
compound.jpg	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$SEEL
Seelos Therapeutics Inc Stock $seel

2015 Q4 Form 10-Q Financial Statement

#000101749115000083 Filed on November 05, 2015

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SEEL Seelos Therapeutics Inc Stock $seel

2015 Q4 Form 10-Q Financial Statement

#000101749115000083 Filed on November 05, 2015

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SEEL
Seelos Therapeutics Inc Stock $seel